香港聯合交易所有限公司與證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本聆訊後資料集全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 CiDi Inc. 希迪智駕科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立之股份有限公司） 的聆訊後資料集 警告 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證 監會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本聆訊後資料集為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、其相關保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據與香港公司註冊處處長註 冊的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據 本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或更換附頁，並不引起本公司 ...

Core Insights - The report discusses the new paradigm of Hong Kong's capital markets driven by technological empowerment and institutional innovation, focusing on the trends and regulations for mainland companies planning to list in Hong Kong by 2025 [1][24]. Listing Pathways - The report highlights the suitability of H-share direct listings and red-chip indirect listings, with a trend towards A-share to H-share conversions. It emphasizes the importance of compliance issues related to VIE structure dismantling, H-share "full circulation," and offshore trust applications [2][18]. - The new regulatory framework established in 2023 has simplified the H-share listing process and optimized the "full circulation" mechanism, providing a more efficient cross-border financing path for large state-owned and mature private enterprises [18][24]. Practical Issues - The report identifies key legal issues for companies planning to list in Hong Kong, including the design of equity incentives, tax planning, and information disclosure, which are critical for executives to manage effectively [2][20]. - The Hong Kong Stock Exchange has introduced initiatives like the "Tech Company Fast Track" to enhance the attractiveness of the market for technology firms, aiming to facilitate their listing processes [2][10]. Hot Industries - The report categorizes key industries such as hard technology, biomedicine, and new consumption, each facing unique compliance challenges. Hard tech companies must navigate intellectual property and export control issues, while biomedicine firms focus on data security and human genetic resource protection [2][22]. - New consumption enterprises face multiple compliance tests, including third-party payment regulations and store licensing management, while domestic chain enterprises must pay attention to franchise compliance and fund management [2][22]. Market Dynamics - By 2025, Hong Kong's capital market is projected to regain its position as the world's top fundraising destination, with over 90% of the companies being from mainland China, driven by institutional innovations that facilitate access to global capital [1][24]. - The report emphasizes that the new regulatory environment and the establishment of a comprehensive filing system mark a significant shift in the cross-border listing landscape, enhancing the market's appeal for innovative enterprises [24].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 CiDi Inc. 希迪智駕科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、各保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據與香港公司註冊處處長註 冊的本公司招股章程作出投資決定。該文件的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據 本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或更換附頁，並不引起本公司、各保薦人、 整體協調 ...

Core Insights - The Hong Kong stock market is increasingly attracting technology companies, with two firms successfully listed under the special Chapter 18C rules as of November 3 [1] - The listing system reforms by the Hong Kong Stock Exchange (HKEX) are accelerating, providing a more inclusive mechanism for tech companies [4] Group 1: Listing Developments - As of November 3, 2023, two companies, Cloudwalk Technology and Deepu Technology, have successfully listed under the HKEX's Chapter 18C [1] - WeRide, which ended its subscription on November 3, is set to officially list on November 6 under the same rules [2] - Currently, there are 16 companies that have submitted applications under Chapter 18C but have not yet listed, spanning sectors like industrial robotics and AI healthcare [3] Group 2: Regulatory Changes - The HKEX introduced Chapter 18C on March 31, 2023, to support tech companies that are not yet profitable or do not meet the main board's revenue requirements [4] - The minimum market capitalization for companies under Chapter 18C was reduced in September 2024, from HKD 60 billion to HKD 40 billion for commercialized companies, and from HKD 100 billion to HKD 80 billion for non-commercialized companies [4] - A new "Tech Company Special Line" was launched in May 2025 to further support tech and biotech companies in their listing efforts [4] Group 3: Focus Areas and R&D Investment - Chapter 18C encompasses five major fields and 20 industries, including new generation information technology, advanced hardware and software, advanced materials, new energy, and agricultural technology [5] - Companies listed under Chapter 18C, such as Cloudwalk Technology and Deepu Technology, have high R&D expenditure relative to their operating costs, with Cloudwalk's R&D investment at 23.4% of its revenue and Deepu's at 33.5% [6] - The requirement for companies to engage in R&D for at least three years before listing under Chapter 18C aims to ensure a focus on innovation and potential commercialization [6] Group 4: Industry Trends - The core sectors for companies under Chapter 18C include service robots and AI applications, with firms focusing on AI-enabled solutions in various industries [7] - The robot industry faces high R&D costs and long commercialization cycles, making the relatively lenient profitability requirements of the Hong Kong market attractive for early-stage companies [7] - Companies are advised to ensure robust intellectual property management and stability of core technical personnel to maintain independent R&D capabilities [8]

Group 1 - The Hong Kong Stock Exchange (HKEX) currently has approximately 280 companies that have submitted A1 listing applications, with about half being technology companies and around 30 being chip-related companies [1] - In recent years, there has been a significant increase in hardware and hard technology companies listing in Hong Kong, compared to earlier years when most were software companies [4] - In 2023, HKEX introduced Chapter 18C to support specialized technology companies in sectors such as semiconductors, robotics and automation, and artificial intelligence to list in Hong Kong [4] Group 2 - In May 2023, the Hong Kong Securities and Futures Commission and HKEX jointly launched the "Tech Company Fast Track," establishing a dedicated team to provide listing guidance for specialized technology companies under Chapter 18C, allowing them to submit materials confidentially [5] - The dedicated consultation service channel enables quality chip companies to seek expert advice before listing [5] - HKEX will regularly update the themes covered under Chapter 18C based on the latest technological trends [5]

Core Viewpoint - The Hong Kong Stock Exchange has introduced Chapter 18C to its Main Board Listing Rules, providing a new listing pathway for specialized technology companies, allowing them to go public even without profitability, similar to the previous 18A listing for biotech companies [1][2]. Company Overview - Yunji Technology, established in 2014 and headquartered in Beijing, is a robotics service company that leverages AI technology to provide robotic services and components [5]. - The company is the fourth specialized technology company to list under Chapter 18C, following Jingtai Technology, Hezhima Intelligent, and Yuejiang Technology [3]. Financial Performance - Yunji Technology's revenue grew from RMB 161.28 million in 2022 to an estimated RMB 244.78 million in 2024, representing a compound annual growth rate (CAGR) of 23.2% [8]. - For the first five months of 2025, the revenue reached RMB 88.33 million, an 18.9% increase compared to the same period in 2024 [8]. - Despite the revenue growth, the company remains in a loss position, with net losses narrowing from RMB 365.42 million in 2022 to RMB 184.96 million in 2024, and a net loss of RMB 118.35 million for the first five months of 2025 [9]. Market Position - In 2024, Yunji Technology held a 6.3% share of the Chinese robotics service market and a leading 13.9% share in the hotel service robotics market, surpassing the combined market share of its competitors [7]. - The hotel segment accounted for 70.1%, 95.1%, and 83.0% of total revenue from 2022 to 2024, with a further increase to 93.2% in the first five months of 2025 [10]. Investment and Financing - Prior to its IPO, Yunji Technology underwent eight rounds of financing, raising approximately RMB 1.2 billion, with notable investors including Tencent, Alibaba, and Ctrip [11]. - The last financing round in December 2021 valued the company at RMB 4.08 billion, but it has not raised funds in the past four years, indicating a lack of confidence in its growth prospects [11]. Industry Outlook - The Chinese hotel robotics market is expected to grow from RMB 1.1 billion in 2023 to RMB 3.6 billion by 2028, with a CAGR of 26.4% [12]. - The competitive landscape is concentrated, with the top five players holding a combined market share of 27.6%, and Yunji Technology leading the market [12]. IPO Details - Yunji Technology plans to issue 6.9 million shares at an offer price of HKD 95.6, with a total market capitalization of HKD 6.57 billion [5][13]. - The IPO is expected to attract significant interest, with a projected oversubscription rate of 4000 times [14].

Core Viewpoint - The Hong Kong IPO market has experienced unprecedented subscription enthusiasm in 2023, with record oversubscription rates and significant increases in both the number of new listings and total fundraising amounts compared to the previous year [1][2]. Group 1: IPO Market Performance - In the first three quarters of 2023, Hong Kong is expected to see 66 new listings, raising a total of HKD 182.3 billion, a 47% increase in the number of new listings and a 228% increase in fundraising compared to the same period last year [1]. - The average first-day return for new IPOs in Hong Kong was 33% in the first half of 2023, significantly higher than the 9% recorded in the same period last year [4]. - The top five new IPOs in 2023 were all large-scale projects raising over HKD 10 billion, with total fundraising for these top five increasing by 135% year-on-year to HKD 98.7 billion [5]. Group 2: Market Dynamics and Trends - The Hong Kong IPO market is benefiting from dual support from policies and capital, with measures from the China Securities Regulatory Commission encouraging leading enterprises to list in Hong Kong [2]. - The average daily trading volume in the Hong Kong stock market has remained above HKD 200 billion, contributing to an overall increase in company valuations [2]. - The financing amounts in the Hong Kong IPO market are diversified across various sectors, with manufacturing leading at 37%, followed by consumer and energy/resource sectors at 20% and 16%, respectively [6]. Group 3: Future Outlook - Deloitte forecasts that the strong momentum in the Hong Kong IPO market will continue into the fourth quarter of 2023, with over 80 new listings expected in 2025, raising between HKD 250 billion and HKD 280 billion [1]. - The Hong Kong government is exploring ways to optimize the "same share, different rights" listing rules to attract more overseas companies for secondary listings [3]. - The market is expected to see continued inflow of overseas capital, particularly as the Federal Reserve enters a rate-cutting cycle, which will support large IPOs in Hong Kong [1][2].

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has introduced a new policy called "Tech Company Special Line," which provides a confidential listing channel and lowers the threshold for specialized technology and biotechnology companies, attracting more tech firms to consider listing in Hong Kong [1][2]. Group 1: Target Audience - Applicable to specialized technology companies (e.g., AI, chips, new energy) and biotechnology companies (e.g., innovative drugs, medical devices), especially those in early stages or with non-commercialized products [3]. Group 2: Eligibility Criteria - Core thresholds include: - Industry attributes: Must belong to HKEX-defined "specialized technology" (Chapter 18C) or "biotechnology" (Chapter 18A) fields. - R&D investment: For specialized technology, R&D spending must account for ≥15% of total costs over the past three years; for biotechnology, core products must have passed Phase I clinical trials. - Commercialization stage: Companies can be unprofitable and have no revenue but must demonstrate technical feasibility and market potential (e.g., patents, letters of intent) [5]. Group 3: Application Process - Step 1: Determine eligibility using the self-assessment tool available on the HKEX website [6]. - Step 2: Submit a confidential application, including signing a Non-Disclosure Agreement (NDA) with HKEX [8]. - Step 3: Provide a "confidential version" of materials, ensuring compliance with format requirements [10]. - Step 4: The HKEX team will provide feedback within 30 days, focusing on technical feasibility and compliance [11]. Group 4: Specialized Services - One-on-one guidance from HKEX experts is available for free, covering listing rules and fundraising strategies [13]. - Qualified companies can benefit from a fast-track review process, reducing the review period to 30 days [14]. - Flexible equity design allows founders to retain control without additional proof of "innovation" [15]. Group 5: Common Pitfalls - Avoid vague technical descriptions; provide third-party certifications and endorsements [17]. - Ensure transparency in related-party transactions; disclose fair pricing evidence [20]. - Strengthen investor relations by involving independent investors and disclosing key investment terms [22]. Group 6: Post-Listing Compliance - Continuous compliance includes mandatory disclosures on commercialization progress and R&D milestones [22]. - Companies can maintain market value by issuing quarterly R&D updates and engaging with analysts [23]. - A green channel for fundraising allows specialized companies to issue new shares through a simplified process [24]. Group 7: Market Comparison - The article compares the listing requirements and processes of Hong Kong (Tech Company Special Line), A-shares (Sci-Tech Innovation Board), and U.S. stocks (NASDAQ), highlighting differences in profitability requirements, review periods, valuation levels, and disclosure pressures [25].

Core Viewpoint - The Hong Kong Securities and Futures Commission (SFC) reported significant growth in the capital market, with a notable increase in fundraising activities and the development of the digital asset ecosystem [2][4]. Group 1: Capital Market Performance - In the first seven months of the year, Hong Kong's fundraising amount surged over 610% year-on-year to HKD 128 billion [2]. - In Q2, there were 27 IPOs raising a total of HKD 88 billion, marking an increase of over 900% compared to the previous year [4]. - The average daily trading volume increased by 85% year-on-year to HKD 243.7 billion [6]. Group 2: IPO Applications and Approvals - As of the end of July, there were over 220 IPO applications under review [2][4]. - The SFC processed 121 new listing applications in Q2, including 11 from unprofitable biotech companies and 11 from specialized technology companies [4]. - The SFC completed the review of 53 accepted listing applications within 40 business days [4]. Group 3: Asset and Wealth Management - The asset and wealth management sector in Hong Kong saw a robust growth, with assets under management for registered funds increasing by 39% year-on-year [6]. - The number of open-end fund companies rose by 56% year-on-year, and the average daily trading volume of ETFs surged by 135.5% [6]. Group 4: Digital Asset Ecosystem - The number of licensed virtual asset trading platforms in Hong Kong increased to 11, with 57 licensed entities allowed to provide virtual asset trading services [8]. - The first six Hong Kong SFC-approved virtual asset spot ETFs saw their market value and average daily trading volume rise by 73% and 13%, respectively [8]. - The SFC issued regulatory guidelines for licensed virtual asset trading platforms regarding collateral services and approved two platforms to offer such services [9].

Core Viewpoint - The market for 18C specialized technology companies in Hong Kong has shifted dramatically from a period of high demand in 2024 to a current state where no IPOs have been completed in 2025, highlighting the challenges these companies face in commercial validation and market expectations [1][9]. Group 1: Market Dynamics - In 2024, 18C specialized technology companies like Jingtai Technology and Hezhima Intelligent were highly sought after, but by 2025, the market has seen no completed IPOs among the 12 companies that have submitted applications [1][9]. - The Hong Kong Stock Exchange implemented reforms on September 1, 2024, lowering the minimum market capitalization requirements for specialized technology companies, with commercialized companies' thresholds reduced from HKD 60 billion to HKD 40 billion [1][9]. Group 2: Company Performance - Three listed 18C companies have shown varied performance, with Jingtai Technology's stock price increasing by 93% since its IPO, while Hezhima Intelligent has seen a decline of 31% [2][6]. - Jingtai Technology raised a total of HKD 32.2 billion through two rounds of financing, significantly exceeding its IPO fundraising of HKD 10.4 billion [4]. - Hezhima Intelligent's stock price fell sharply after a secondary offering at a discount to its IPO price, reflecting concerns over its financial performance and lack of clarity in earnings forecasts [6]. Group 3: Financial Metrics - Jingtai Technology's R&D spending was substantial, with 2024 expenditures at HKD 4.18 billion, representing 157% of its revenue [8]. - Hezhima Intelligent reported a revenue of RMB 4.74 billion for 2024, but also disclosed a significant adjusted net loss of RMB 13.04 billion, raising questions about its profitability despite revenue growth [6][11]. - The company Yujiang, despite being the smallest at IPO with a market cap of HKD 75 billion, has seen its stock price rise by 188%, although its financial performance remains weak with a net loss of RMB 0.95 billion [7][10]. Group 4: Future Outlook - The 12 companies that have submitted IPO applications in 2025 have met the commercial revenue threshold of HKD 2.5 billion, but many are struggling with weak fundamentals and unclear commercialization paths [11]. - Companies like Xidi Zhijia and Wuyi Vision are facing regulatory pressures and have yet to receive feedback from the securities regulatory authority, indicating potential challenges in their IPO processes [12].